The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy

Documenti analoghi

• A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study
  di: Fatih Gürler, et al.
  Pubblicazione: (2024)
• Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008
  di: Yoshinori Imamura, et al.
  Pubblicazione: (2024)
• Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
  di: Guihong Liu, et al.
  Pubblicazione: (2024)
• The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin‐based chemoradiotherapy in patients with head and neck squamous cell carcinoma
  di: Anouk W. M. A. Schaeffers, et al.
  Pubblicazione: (2024)
• Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma
  di: Qing Liu, et al.
  Pubblicazione: (2024)